

STERiJECT™ Low Dead Space Intravitreal Injection Needles.

FDA 510(k) cleared

Low dead space

Optimal TSKiD

30G, 32G, 33G, 34G

Ophthalmic Use


Accurate dosing

Best flow rate

Optimal comfort



STERiJECT™ Low Dead Space Intravitreal Injection Needles.



Ophthalmic intended use.

FDA 510(k), PMDA cleared
For intravitreal use.

MDR, MDL pending
For intravitreal use.

USP 789 testing per batch
Testing results per batch available.

Low particulate count
Compliant to USP 789 (788)

Endotoxin limit 0.2 EU/device
Reduced risk for acute inflammation


Effortless insertion and reduced vitreous drag.

STERiJECT Ophthalmic Low Dead Space Needle features a sharp bevel for smoother penetration, improving patient comfort and reducing peak entry force^[3]. The dolphin nose glue dome minimizes abrasion, preserving needle and tissue integrity.

Launching in 30G, 32G, 33G, and 34G sizes, our micro-needles lower insertion force and reflux risk^{[1][3]}. A proprietary coating ensures effortless gliding and reduces vitreous drag for better control.

A full range of gauges and lengths, including a 4mm recommended in the SAFER protocol for injecting premature infants^[2], supports every treatment stage. The capsule case ensure easy assembly and reduced risk of needle injury.


Lowest insertion force.



Optimal needle sharpness.

STERiJECT 33G Ophthalmic Needle penetration force is 0.014 N lower than competitor needles^[3].


Minimal needle flexibility.



Up to 40% more rigid.

STERiJECT 33G Ophthalmic Needle bending distance is 0.10 mm shorter than competitor needle^[3].


Lowest extrusion force.



Best flow rate.

STERiJECT 33G Ophthalmic Needle achieved the highest flow rate of product passing through the barrel^[3].

High pop-off resistance.



Up to 22% less pop-off risk.

STERiJECT 34G Ophthalmic Needle could withstand 11N higher force before pop-off occurred^[3].

References STERiJECT™.

[1] Association Between Needle Size, Postinjection Reflux, and Intraocular Pressure Spikes after Intravitreal Injections. *Retina* 35(7): p 1401-1406, July 2015.


[2] Technique for Infant Intravitreal Injection in Treatment of Retinopathy of Prematurity *Retina* 37(11): p 2188-2190, November 2017.

[3] Internal testing by TSK Laboratory International Japan, March 2025, compliant with ISO7864:2016, ISO9626:2016.

[4] Introducing TSK Low Dead Space Needles For Anti-VEGF Injections, TSK Laboratory Europe BV, October 2020.

Accurate dose delivery.

Loss: 0.042 ml^[4] Loss: ~0.0 ml



Traditional hub

Low Dead Space hub

Available needle size for intravitreal injections:

#	Description	Gauge	Length	Code
1.	STERiJECT OPHTHALMIC NDL LDS 0.30/13mm	30 G	13 mm	VLDS-30013E
2.	STERiJECT OPHTHALMIC NDL LDS 0.26/4mm	32 G	4 mm	VLDS-32004R
3.	STERiJECT OPHTHALMIC NDL LDS 0.26/9mm	32 G	9 mm	VLDS-32009R
4.	STERiJECT OPHTHALMIC NDL LDS 0.26/13mm	32 G	13 mm	VLDS-32013R
5.	STERiJECT OPHTHALMIC NDL LDS 0.24/9mm	33 G	9 mm	VLDS-33009R
6.	STERiJECT OPHTHALMIC NDL LDS 0.24/13mm	33 G	13 mm	VLDS-33013R
7.	STERiJECT OPHTHALMIC NDL LDS 0.20/9mm	0.2	9 mm	VLDS-02009R

Questions? We are happy to assist you.

TSK Laboratory Europe B.V.
De Scheper 309
5688HP Oirschot
The Netherlands

+31 (0) 85 760 7630
europe@tsklab.com

WWW.TSKLAB.COM

STERiJECT™ trusted globally in ophthalmology.

Over 50 years of expertise in specialty needle manufacturing

Preferred partner for leading global pharmaceutical companies

Reliable ophthalmic compliance and quality support departments

World wide representation
ISO 13485, ISO 9001, FDA,
MDR/MDD, MDL, PMDA.